57th ASH Annual Meeting and Exposition (December 5-8, 2015): 102. Regulation of Iron Metabolism: Iron Metabolism

Regulation of Iron Metabolism Oral and Poster Abstracts
Oral

W414AB, Level 4 (Orange County Convention Center)

Moderators:

Maria Domenica Cappellini, MD, Ca'Granda Foundation IRCCS, Ospedale Maggiore and Robert E Fleming, MD, Saint Louis University School of Medicine

Disclosures:

No relevant conflicts of interest to declare.

10:30 AM

535

Erfe-Encoding FAM132B in Congenital Dyserythropoietic Anemia Type II

Roberta Russo^1,2^*, Immacolata Andolfo^1,2^*, Luigia De Falco^1,3^*, Francesco Manna²^*, Antonella Gambale^1,4^*, Mariasole Bruno^1,5^*, Gianluca De Rosa¹^*, Domenico Girelli, MD, PhD⁶, Lucia De Franceschi, MD⁵ and Achille Iolascon, MD, PhD^1,4

¹CEINGE Biotecnologie Avanzate, Napoli, Italy
²CEINGE, Biotecnologie Avanzate, Naples, Italy, Department of Molecular Medicine and Medical Biotechnologies, “Federico II” University of Naples, Naples, Italy, Napoli, Italy
³Department of Molecular Medicine and Medical Biotechnologies, “Federico II” University of Naples, Naples, Italy
⁴Dipartimento di Medicina Molecolare e Biotecnologie Mediche, Università degli Studi di Napoli Federico II, Napoli, Italy
⁵Department of Medicine, University of Verona and AOUI-Verona, Verona, Italy
⁶Department of Medicine, Section of Internal Medicine, University of Verona, Policlinico G.B. Rossi, Verona, Italy

10:45 AM

536

A Phase I Study Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Activity of the Hepcidin Antagonist PRS-080#022. Results from a Randomized, Placebo Controlled, Double-Blind Study Following Single Administration to Healthy Subjects^a

Ulrich Moebius, PhD¹^*, Werner Feuerer, MD²^*, Edgar Fenzl, MD³^*, Rachel van Swelm, PhD⁴^*, Dorine W. Swinkels, MD, PhD⁴ and Andreas Hohlbaum, PhD¹^*

¹Pieris Pharmaceuticals Inc., Boston, MA
²Nuvisan Pharma Services, Neu-Ulm, Germany
³FGK Clinical Research, Munich, Germany
⁴Radboud University Medical Centre, Nijmegen, Netherlands

11:00 AM

537

Phase 1 Study of a Hepcidin Antagonist, LY2787106, in Cancer-Associated Anemia

Saroj Vadhan-Raj, MD¹, Rafat Abonour², Jonathan W. Goldman, MD³^*, David A. Smith, MD⁴, Christopher A. Slapak, MD⁵, Ramon V. Tiu, MD⁵, Xuejing Wang⁵^*, Sophie Callies⁶^*, Joanne Cox⁷^*, Jay L. Tuttle, PhD⁵^*, Yiu-Keung (James) Lau, MD, PhD⁵ and Eric J. Roeland, MD⁸^*

¹UT M.D. Anderson Cancer Center, Houston, TX
²Indiana University Simon Cancer Center, Indianapolis, IN
³University of California, Los Angeles, Santa Monica, CA
⁴Compass Oncology, Vancouver, WA
⁵Eli Lilly and Company, Indianapolis, IN
⁶Eli Lilly and Company, Neuilly-sur-Seine, France
⁷Eli Lilly and Company, Surrey, United Kingdom
⁸Moores Cancer Center, University of California San Diego, La Jolla, CA

11:15 AM

538

The Jak1/Jak2 Inhibitor Momelotinib Inhibits Alk2, Decreases Hepcidin Production and Ameliorates Anemia of Chronic Disease (ACD) in Rodents

Malte Asshoff, MD¹^*, Matthew Warr, PhD²^*, David Haschka, MD¹^*, Piotr Tymoszuk, PhD¹^*, Verena Petzer¹^*, Egon Demetz, PhD¹^*, Pat Maciejewski, Phd²^*, Markus Seifert¹^*, Manfred Nairz, MD, PhD¹^*, Wilfried Posch, PhD³^*, Peter Fowles²^*, Guenter Weiss, MD¹^*, Andy Whitney²^* and Igor Theurl, MD, PhD¹^*

¹Internal Medicine VI, Medical University of Innsbruck, Innsbruck, Austria
²Gilead Sciences, Branford, CT
³Divsison of Hygiene and Medical Microbiology, Medical University of Innsbruck, Innsbruck, Austria

11:30 AM

539

Residual Erythropoiesis Protects Against Cardiac Iron Loading in Transfusion Dependent Thalassaemia (TDT) By Lowering Labile Plasma Iron (LPI) through Transient Apotransferrin Generation

Maciej W. Garbowski, MD^1,2^*, Patricia Evans, PhD²^* and John B Porter^1,2^*

¹Haematology Department, University College London Hospitals, London, United Kingdom
²University College London, London, United Kingdom

11:45 AM

540

Prevalence of Cardiac and Hepatic Siderosis in Australian Patients with Transfusion-Dependent Anemias or Non-Transfusion-Dependent Thalassemia, As Assessed By MRI (the TIMES study)

Phoebe Joy Ho¹, Devendra Hiwase, MBBS, FRACP, FRCPA, MD, PhD², Raj Ramakrishna³^*, Nicholas Viiala⁴^*, David M Ross, MBBS, PhD, FRACP, FRCPA⁵^*, Evren Zor⁶^*, Othon L Gervasio⁷^* and Donald Bowden⁸^*

¹Royal Prince Alfred Hospital, Sydney Medical School, Sydney, Australia
²Haematology, SA Pathology, Adelaide, Australia
³Southern Sydney Haematology, Kogarah, Sydney, Australia
⁴Liverpool Hospital, Sydney, Australia
⁵Flinders Medical Centre, Adelaide, Australia
⁶Novartis Pharmaceuticals Australia Pty Limited, North Ryde, Australia
⁷Novartis Pharmaceuticals, Sydney, Australia
⁸Monash Medical Centre, Melbourne, Australia

See more of: Regulation of Iron Metabolism
See more of: Oral and Poster Abstracts

<< Previous Session | Next Session >>

^*signifies non-member of ASH

102.O2.6 102. Regulation of Iron Metabolism: Iron Metabolism – Clinical and Translational